Journal article · 2025 · Open access

The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia

Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, An Snellinx, Ciana Xu, Suresh Kumar Poovathingal, Marta Wojno, Kristofer Davie, Veerle van Lieshout, Katleen Craessaerts, Leen Wolfs, Emanuela Pasciuto and 6 more

Nature Neuroscience, 29(1), 100–110 · Published 24 November 2025 · DOI 10.1038/s41593-025-02125-8

Open full textCite this paper

In brief

“The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia” is a 2025 journal article by Giulia Albertini and 17 co-authors, published in Nature Neuroscience. OpenAlex counts 69 citations as of 16 November 2026, which puts it in the top 5% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Nature Neuroscience.

Citations
69
Most cited in
2026 (65)
Field-weighted impact
16.57
References
63
Authors
18

Abstract

Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions. Using a human microglia xenograft mouse model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither fragment crystallizable (Fc)-silenced Lecanemab nor microglia deficiency elicits this effect despite intact plaque binding. Single-cell RNA sequencing and spatial transcriptomic analyses reveal that Lecanemab induces a focused transcriptional program that enhances phagocytosis, lysosomal degradation, metabolic reprogramming, interferon γ genes and antigen presentation. Finally, we identify SPP1/osteopontin as a major factor induced by Lecanemab treatment and demonstrate its role in promoting Aβ clearance. These findings highlight that effective amyloid removal depends on the engagement of microglia through the Fc fragment, providing critical insights for optimizing anti-amyloid therapies in Alzheimer's disease.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Albertini, G., Zielonka, M., Cuypers, M., Snellinx, A., Xu, C., Poovathingal, S. K., Wojno, M., Davie, K., van Lieshout, V., Craessaerts, K., Wolfs, L., Pasciuto, E., Jaspers, T., Horré, K., Serneels, L., Fiers, M. W. E. J., Dewilde, M., & De Strooper, B. (2025). The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia. Nature Neuroscience, 29(1), 100–110. https://doi.org/10.1038/s41593-025-02125-8

MLA 9

Albertini, Giulia, et al. “The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.” Nature Neuroscience, vol. 29, no. 1, 2025, pp. 100–110. https://doi.org/10.1038/s41593-025-02125-8.

Chicago

Albertini, Giulia, Magdalena Zielonka, Marie‐Lynn Cuypers, An Snellinx, Ciana Xu, Suresh Kumar Poovathingal, Marta Wojno, et al. 2025. “The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.” Nature Neuroscience 29 (1): 100–110. https://doi.org/10.1038/s41593-025-02125-8.

Harvard

Albertini, G. et al. (2025) ‘The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia’, Nature Neuroscience, 29(1), pp. 100–110. doi:10.1038/s41593-025-02125-8.

IEEE

G. Albertini et al., “The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia,” Nature Neuroscience, vol. 29, no. 1, pp. 100–110, 2025, doi: 10.1038/s41593-025-02125-8.

BibTeX

@article{albertini2025alzheimer,
  title     = {{The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia}},
  author    = {Albertini, Giulia and Zielonka, Magdalena and Cuypers, Marie‐Lynn and Snellinx, An and Xu, Ciana and Poovathingal, Suresh Kumar and Wojno, Marta and Davie, Kristofer and van Lieshout, Veerle and Craessaerts, Katleen and Wolfs, Leen and Pasciuto, Emanuela and Jaspers, Tom and Horré, Katrien and Serneels, Lutgarde and Fiers, Mark W. E. J. and Dewilde, Maarten and De Strooper, Bart},
  journal   = {Nature Neuroscience},
  year      = {2025},
  volume    = {29},
  number    = {1},
  pages     = {100--110},
  doi       = {10.1038/s41593-025-02125-8},
  url       = {https://doi.org/10.1038/s41593-025-02125-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • lecanemab
  • anti-amyloid immunotherapy
  • amyloid-beta clearance
  • microglia
  • Alzheimer's disease
  • Fc fragment
  • phagocytosis
  • lysosomal degradation

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Albertini, G., Zielonka, M., Cuypers, M., Snellinx, A., Xu, C., Poovathingal, S. K., Wojno, M., Davie, K., van Lieshout, V., Craessaerts, K., Wolfs, L., Pasciuto, E., Jaspers, T., Horré, K., Serneels, L., Fiers, M. W. E. J., Dewilde, M., & De Strooper, B. (2025). The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia. Nature Neuroscience, 29(1), 100–110. https://doi.org/10.1038/s41593-025-02125-8

How many times has this paper been cited?

69 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Neuroscience: sign in and open the full text from this page.

Who wrote this paper?

Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, An Snellinx, Ciana Xu, Suresh Kumar Poovathingal, Marta Wojno, Kristofer Davie, Veerle van Lieshout, Katleen Craessaerts, Leen Wolfs, Emanuela Pasciuto and 6 more.

What is the DOI of this paper?

10.1038/s41593-025-02125-8, permanently at https://doi.org/10.1038/s41593-025-02125-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.